# DMR-001

Source: https://onco.cc/drugs/dmr-001/  
OnCo record `dmr-001` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

DMR-001 is an experimental monoclonal antibody from Damora Therapeutics, in phase 1 trials for CALR-mutant essential thrombocythaemia and CALR-mutant myelofibrosis.

## Summary

DMR-001 is a monoclonal antibody (subcutaneous, half-life extended) from Damora Therapeutics. An antibody designed to bind only mutant calreticulin (mutCALR), the driver of some myeloproliferative neoplasms, with half-life extension intended to allow infrequent subcutaneous dosing. Its furthest stage is phase 1, for CALR-mutant essential thrombocythaemia and CALR-mutant myelofibrosis. ClinicalTrials.gov registers it in one study linked below. Global phase 1/1b CLARITY-101 started mid-2026 (NCT07849231, recruiting). Whether it works in people has not been established unless a trial below reports it.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Code: DMR-001
- Modality: Monoclonal antibody (subcutaneous, half-life extended)
- Mechanism: An antibody designed to bind only mutant calreticulin (mutCALR), the driver of some myeloproliferative neoplasms, with half-life extension intended to allow infrequent subcutaneous dosing.

## Sources

- Damora Therapeutics: damoratx.com: https://damoratx.com/
- Damora Therapeutics: damoratx.com: https://damoratx.com/
- Damora Therapeutics: clinicaltrials.gov: https://clinicaltrials.gov/study/NCT07849231
- ClinicalTrials.gov: trials of DMR-001: https://clinicaltrials.gov/search?intr=DMR-001

## Connected records

- cancers: [Essential thrombocythaemia (ET)](https://onco.cc/cancers/essential-thrombocythaemia/), [Primary myelofibrosis](https://onco.cc/cancers/primary-myelofibrosis/)
- targets: [CALR](https://onco.cc/targets/calr/)
- companies: [Damora Therapeutics](https://onco.cc/companies/damora-therapeutics/)
- trials: [A Study to Evaluate DMR-001 in Participants With CALR-mutant Myeloproliferative Neoplasms](https://onco.cc/trials/nct07849231/)

---
JSON: https://onco.cc/api/v1/entities/dmr-001.json